MedTrace Logo

A Randomized, Single-blind, Parallel Group and Multiple - Dose Design Study

NCT03451487 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2023-07-18

No results posted yet for this study

Summary

To investigate and compare the possible response of Panadol® and SafeTynadol® formulations in healthy volunteers.

Conditions

  • Acetaminophen Toxicity

Interventions

DRUG

Panadol®

Acetaminophen 500mg Tablet

DRUG

SafeTynadol®

Acetaminophen 500mg Tablet

Sponsors & Collaborators

  • Sinew Pharma Inc.

    lead INDUSTRY

Principal Investigators

  • TeYu Mr Lin, Dr. · Principal Investigator

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-05-19
Primary Completion
2022-12-31
Completion
2022-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03451487 on ClinicalTrials.gov